Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)

Brief summary (registry, in English)

Dose-Escalation Phase (Phase 1) Primary objective: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 combined with chemotherapy (topotecan day 1 to 5 every 3 weeks; carboplatin day 1 plus etoposide days 1, 2 and 3 every 3 weeks) in patients with SCLC. Expansion Phase (Phase 2): Primary objective To evaluate the overall response rate (ORR) and disease control rate (DCR) of IDP-121 combined with chemotherapy in patients with SCLC.

What you commit to

• Study type: Interventional · Phase 1/2
• Planned participants: 60
• 10 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (10)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details